Prelude Capital Management’s CareDx CDNA Stock Holding History

Prelude Capital Management’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$391K	–	1169
2025 Q2	$391K	Buy	20,000 +8,300	+71%	+$147K	0.04%	516
2025 Q1	$208K	Buy	+11,700	New	+$252K	0.02%	924
2020 Q3	–	Sell	-10,502	Closed	-$372K	–	1874
2020 Q2	$372K	Buy	10,502 +5,582	+113%	+$159K	0.02%	557
2020 Q1	$107K	Sell	4,920 -11,888	-71%	-$266K	0.01%	577
2019 Q4	$363K	Sell	16,808 -2,043	-11%	-$46.9K	0.01%	658
2019 Q3	$426K	Sell	18,851 -11,067	-37%	-$306K	0.02%	566
2019 Q2	$1.08M	Buy	29,918 +11,211	+60%	+$359K	0.05%	328
2019 Q1	$590K	Buy	18,707 +11,037	+144%	+$322K	0.03%	456
2018 Q4	$193K	Sell	7,670 -400	-5%	-$10.3K	0.01%	741
2018 Q3	$233K	Sell	8,070 -28,550	-78%	-$534K	0.01%	729
2018 Q2	$448K	Buy	36,620 +1,500	+4%	+$17.2K	0.03%	562
2018 Q1	$280K	Buy	35,120 +9,600	+38%	+$59.2K	0.02%	601
2017 Q4	$187K	Buy	+25,520	New	+$159K	0.02%	624

Other funds holding CDNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OAM

Ophir Asset Management Sydney, Australia $859M AUM 59.08% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Prelude Capital Management's CDNA Position: Q3 2025 in Review

Prelude Capital Management sold out of CareDx (CDNA) in Q3 2025, closing a stake of 20,000 shares — an estimated $391K sold.

Prelude Capital Management first reported a position in CDNA in Q4 2017 and held it in 13 quarters. The position peaked at $1.08M in Q2 2019. 187 funds tracked by Wall St. Rank hold CDNA as of Q3 2025.

Prelude Capital Management reported no remaining CareDx position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 20,000 CareDx shares in Q3 2025, an estimated $391K.
Prelude Capital Management first reported a position in CareDx in Q4 2017 and held it in 13 quarters.
Prelude Capital Management's CareDx position peaked at $1.08M in Q2 2019.
187 funds tracked by Wall St. Rank held CareDx as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.